Semnur Pharmaceuticals, Inc.
SMNR
$0.55
-$0.01-1.79%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 498.59% | 592.47% | 906.28% | 14,120.75% | -37.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 322.82% | 588.12% | 693.56% | 11,656.09% | -10.00% |
| Operating Income | -322.82% | -588.12% | -693.56% | -11,656.09% | 10.00% |
| Income Before Tax | -335.14% | -588.12% | -693.56% | -11,656.09% | 10.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -335.14% | -588.12% | -693.56% | -11,656.09% | 10.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -335.14% | -588.12% | -693.56% | -11,656.09% | 10.00% |
| EBIT | -322.82% | -588.12% | -693.56% | -11,656.09% | 10.00% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -278.00% | -503.03% | -625.64% | -11,540.00% | 27.54% |
| Normalized Basic EPS | -280.65% | -490.48% | -637.50% | -11,434.15% | 27.91% |
| EPS Diluted | -278.00% | -503.03% | -625.64% | -11,540.00% | 27.54% |
| Normalized Diluted EPS | -280.65% | -490.48% | -637.50% | -11,434.15% | 27.91% |
| Average Basic Shares Outstanding | 15.10% | 15.10% | 8.72% | 0.84% | 25.00% |
| Average Diluted Shares Outstanding | 15.10% | 15.10% | 8.72% | 0.84% | 25.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |